Zelpultide alfa

Phase 3Peptide

AAirway Therapeutics, Inc.

Zelpultide alfa is one of 13 small molecule programs targeting Bronchopulmonary Dysplasia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bronchopulmonary DysplasiaRecruiting

Bronchopulmonary DysplasiaPhase 3

Recruiting

Competition

Competitive Landscape

16 competitors in Bronchopulmonary Dysplasia

#DrugCompanyPhaseTrials

Biaxin

Pulmicort

2 3

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—4

Tobrex

VViatris Specialty LLC

Qvar

CUROSURF

Chiesi Farmaceutici S.p.A.

Approved

1 7

Immunoglobulin

Sanofi

Phase 2

1 8

Intravenous Immunoglobulin

UUniversity of Alabama at Birmingham

Phase 2

1 9

Glucophage

EMD Serono

Phase 1

1 10

Zelpultide alfa

AAirway Therapeutics, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

PreclinicalRecruiting

Bronchopulmonary Dysplasia

NCT06897839

Clinical

Trials by Indication[1]

Bronchopulmonary Dysplasia1 trial

Randomized, Double-Blind Parallel-Group, Adaptive, Three-Arm, Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing Bronchopulmonary Dysplasia (BPD) in High-Risk Preterm Neonates Compared to Standard of Care (SOC)

Recruiting·AAirway Therapeutics, Inc.·Preclinical·NCT06897839·366 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zelpultide alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zelpultide alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zelpultide alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Airway Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: AAirway Therapeutics, Inc.

Zelpultide alfa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Bronchopulmonary Dysplasia1 trial

References

Drug Info

Quick Facts

Related News